WO2013039764A1 - Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients - Google Patents
Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients Download PDFInfo
- Publication number
- WO2013039764A1 WO2013039764A1 PCT/US2012/054046 US2012054046W WO2013039764A1 WO 2013039764 A1 WO2013039764 A1 WO 2013039764A1 US 2012054046 W US2012054046 W US 2012054046W WO 2013039764 A1 WO2013039764 A1 WO 2013039764A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- dose
- patient
- days
- benzimidazol
- methylpiperazin
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 25
- 230000002440 hepatic effect Effects 0.000 title claims abstract description 21
- 230000001771 impaired effect Effects 0.000 title claims abstract description 19
- 201000011510 cancer Diseases 0.000 title claims abstract description 16
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 title claims abstract description 11
- 238000011282 treatment Methods 0.000 title description 34
- 150000003839 salts Chemical class 0.000 claims abstract description 11
- 238000000034 method Methods 0.000 claims abstract description 10
- 108010082126 Alanine transaminase Proteins 0.000 claims description 24
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 claims description 23
- 108010003415 Aspartate Aminotransferases Proteins 0.000 claims description 20
- 102000004625 Aspartate Aminotransferases Human genes 0.000 claims description 20
- 238000008050 Total Bilirubin Reagent Methods 0.000 claims description 6
- 150000003893 lactate salts Chemical group 0.000 claims description 3
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 3
- ZRHDKBOBHHFLBW-UHFFFAOYSA-N 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one 2-hydroxypropanoic acid Chemical compound CC(O)C(O)=O.C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 ZRHDKBOBHHFLBW-UHFFFAOYSA-N 0.000 claims description 2
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims 2
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 37
- 208000019423 liver disease Diseases 0.000 description 23
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 16
- 230000003908 liver function Effects 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 231100000371 dose-limiting toxicity Toxicity 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 210000003494 hepatocyte Anatomy 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 201000009613 breast lymphoma Diseases 0.000 description 3
- 230000006735 deficit Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 208000037844 advanced solid tumor Diseases 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000027700 hepatic dysfunction Diseases 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000036962 time dependent Effects 0.000 description 2
- YUDPTGPSBJVHCN-DZQJYWQESA-N 4-methylumbelliferyl beta-D-galactoside Chemical compound C1=CC=2C(C)=CC(=O)OC=2C=C1O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O YUDPTGPSBJVHCN-DZQJYWQESA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 101100492584 Caenorhabditis elegans ast-1 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 102000008142 Cytochrome P-450 CYP1A1 Human genes 0.000 description 1
- 108010074918 Cytochrome P-450 CYP1A1 Proteins 0.000 description 1
- 238000008789 Direct Bilirubin Methods 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 101710107035 Gamma-glutamyltranspeptidase Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 101710173228 Glutathione hydrolase proenzyme Proteins 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000022120 Jeavons syndrome Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- -1 LDH Proteins 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 1
- 102000006640 gamma-Glutamyltransferase Human genes 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000010197 meta-analysis Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000011301 standard therapy Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 108010002164 tyrosine receptor Proteins 0.000 description 1
- 231100000402 unacceptable toxicity Toxicity 0.000 description 1
- 238000002562 urinalysis Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a method of treating a cancer in a patient in need thereof by administering 4-amino-5-fluoro-3-[6-(4-methylpiperazin-l-yl)-lH- benzimidazol-2-yl]-lH-quinolin-2-one, or a tautomer thereof, or a salt of any one of them (COMPOUND I), wherein the patient is a moderate hepatic impaired patient.
- the compound of Formula I inhibits various protein kinases, such as tyrosine receptor protein kinases.
- Use and preparation of this compound and its salts, including the mono- lactic acid salt, are described in U.S. Patent Nos. 6,605,617, 6,774,237, 7,335,774, and 7,470,709, and in U.S. Patent Application Serial Nos. 10/982,757, 10/982,543, and 10/706,328, and in the published PCT applications WO2006/127926, published on November 30, 2006 and WO2009/115562 published on September 24 th , 2009, each of which is incorporated herein by reference in its entirety. Crystalline forms and their preparations are described in USl 1/915005, in particular Form B. [0005] Based on PK and safety data of COMPOUND I from Phase I and II studies, the
- COMPOUND I can be administered to those patients at the same dose as the normal hepatic and mild hepatic impaired patients.
- Patient with hepatic impairment might be at higher risk to have a decreased ability to eliminate COMPOUND I.
- Decrease drug clearance as a result of impaired organ function can lead to an increased systemic exposure and possible toxicity.
- the inventors of the present case are solving the current problem with the present invention.
- the present invention pertains to COMPOUND I for use in the treatment of cancer in a patient in need thereof wherein said patient a moderate hepatic impaired patient and wherein the dose administered is 400 mg per day and the dose schedule is 5 days on and 2 days off.
- the present invention pertains to COMPOUND I for use in the treatment of cancer in a patient in need thereof wherein said patient a moderate hepatic impaired patient and wherein the dose administered is 500 mg per day and the dose schedule is 5 days on and 2 days off.
- the present invention pertains to COMPOUND I for use in the treatment of cancer in a patient in need thereof wherein said patient a moderate hepatic impaired patient and wherein the dose administered is 300 mg per day and the dose schedule is 5 days on and 2 days off.
- the present invention pertains to methods of treating a patient having a cancer by administering 4-amino-5-fluoro-3-[6-(4-methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH- quinolin-2-one or a tautomer or a salt of either of them, wherein the patient is a moderate hepatic impaired patient and wherein the dose is 300 mg, 400mg or 500 mg per day and the dose schedule is 5 days on and 2 days off.
- the present invention pertains to the use of 4-amino-5-fluoro-3-[6-(4- methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one or a tautomer or a salt of either of them for the preparation of a medicament for the treatment of cancer wherein the patient is moderate hepatic impaired patient and the dose administered is 300 mg or 400 mg or 500 mg per day and the dose schedule is 5 days on and 2 days off.
- Cancers treated according to the present invention include solid tumors, such as renal, breast, bladder, prostate cancer, and multiple myeloma.
- a moderate hepatic impaired patient is a patient having the following plasma characteristics : 1.5 x ULN ⁇ TBL ⁇ 3.0 x ULN and/or AST and ALT ⁇ 5 x ULN wherein ULN means upper limit normal, TBL means total bilirubin, AST means aspartate transaminase, ALT means alanine transaminase.
- ALT Alanine transaminase
- SGPT hepatocytes
- LAT Alanine aminotransferase
- ALT rises dramatically in acute liver damage, such as viral hepatitis or paracetamol (acetaminophen) overdose. Elevations are often measured in multiples of the upper limit of normal (ULN).
- the reference range for ALT is 9 to 40 IU/L (international units per liter).
- Aspartate transaminase also called Serum Glutamic Oxaloacetic
- Transaminase or aspartate aminotransferase (ASAT) is similar to ALT in that it is another enzyme associated with liver parenchymal cells. It is raised in acute liver damage.
- AST id 10 to 35 IU/L.
- Bilirubin is a breakdown product of heme (a part of hemoglobin in red blood
- the liver is responsible for clearing the blood of bilirubin. It does this by the following mechanism: Bilirubin is taken up into hepatocytes, conjugated (modified to make it water-soluble), and secreted into the bile, which is excreted into the intestine. Increased total bilirubin causes jaundice, and can signal a number of problems. Problems with the liver, which are reflected as deficiencies in bilirubin metabolism (e.g., reduced hepatocyte uptake, impaired conjugation of bilirubin, and reduced hepatocyte secretion of bilirubin).
- the normal level of total bilirubin is for example, the reference range of 0.2- 1.2 mg/dL.
- AST, ALT and/or TBL measure the blood and/or plasma levels of AST, ALT and/or TBL, e.g. according to the FDA and/or the EMEA standard and knows how to stratify a patient as moderate impaired patient based on the results of the measurements of AST, ALT and/or TBL.
- Suitable salts include any pharmaceutically acceptable salt, especially the lactate salt form, such as the mono-lactic acid salt form. Additional pharmaceutically acceptable salts are known to those of skill in the art.
- the lactate salt of COMPOUND I can be 4- amino-5-fluoro-3-[6-(4-methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one lactate in crystalline Form B, as described in US 11/915005.
- Example 1 Pharmacokinetics of Compound I (4-amino-5-fluoro-3-[6-(4- methylpiperazin-l-yl)-lH-benzimidazol-2-yl]-lH-quinolin-2-one or a tautomer thereof e.g. in the lactic acid salt form thereof), in adult cancer patients with normal and moderate impaired hepatic functions
- PK pharmacokinetics
- COMPOUND I pharmacokinetics
- Study population Adult patients who have advanced solid tumor (except breast cancer and lymphoma) that is either refractory to the standard therapy or has no available therapies with varying degrees of hepatic impairment according to NCI guidelines and matching cancer patients with normal hepatic function.
- steady state PK of COMPOUND I is also determined following multiple dosing of COMPOUND I for 3 weeks or 4 weeks (in case a patient missed or was unable to have a satisfying PK sampling following 3 weeks of dosing) in these patients.
- the study consists of 4 treatment groups, including Treatment Groups 1 (normal hepatic function) and 2 (mild hepatic impairment), 3 (moderate hepatic impairment). All treatment groups enroll patients with any solid tumor except breast cancer and lymphoma.
- Treatment Group 3 Moderate hepatic dysfunction
- 400 mg/day 5 days on/2 days off dose schedule
- other dose levels 500 mg/day or 300 mg/day
- Treatment Group 3 may be explored in patients with moderate hepatic dysfunction based on safety, tolerability, and PK data obtained during this study.
- Treatment duration includes a single-dose PK period with a single dose of COMPOUND I administrated on Day 1 of Week 1 and multiple-dose treatment period with COMPOUND I, e.g. on a 5 days on/2 days off dosing regimen, starting on Day 4 of Week 1 until disease progression, e.g. assessed by RECIST 1.1, unacceptable toxicity, death or discontinuation from the study treatment for any other reason.
- Approximately 18-48 patients are enrolled in 3 treatments groups based on their total bilirubin and AST/ ALT levels at baseline/screening. Table below details patient allocation and treatment dose for each treatment group.
- the enrollment to the Treatment Groups 1-3 are in parallel, with at least 6 evaluable patients per treatment group.
- the mild hepatic impairment group requires 6- 12 evaluable patients.
- the moderate hepatic impairment group may require 6-18 evaluable patients.
- At least 6 patients are evaluated for PK at the identified tolerated COMPOUND I dose.
- the enrollment to Treatment Group 1 (control) is comparable (or similar) to the enrollment to Treatment Groups 2 (mild hepatic impairment) and 3 (moderate hepatic impairment), with respect to age ( ⁇ 10 years) and body weight ( ⁇ 10 Kg). Therefore, the enrollment of Treatment Group 1 (normal hepatic function) remain open until the enrollment in the mild and moderate hepatic impairment groups is complete, and a sufficient number of matching controls has been achieved for comparison, with a minimum of 6 evaluable patients in this treatment group.
- a dose de-escalation to 400 mg is allowed for Treatment Group 2 (mild hepatic impairment), and to 300 mg for Treatment Group 3 (moderate hepatic impairment).
- Dose-limiting toxicities (DLT) criteria is used to guide dose escalation or dose de-escalation to identify the tolerated COMPOUND I dose in Treatment Groups 2 and 3 based on the dose levels assessed in this study.
- An evaluable patient is required to complete both safety (DLT evaluation) and PK assessments. A patient is considered PK evaluable if a complete PK profile is obtained at the single dose PK period and at steady state.
- a patient is considered evaluable for DLT if the patient completed 4 weeks of COMPOUND I treatment receiving at least 16 doses of the planned dose on a 5 days on / 2 days off dosing regimen, or is discontinued from COMPOUND I treatment due to the DLT within 4 weeks on a
- PK assessment A total of 17 time points and approximately 34 mL of blood per patient is collected after starting COMPOUND I treatment. Blood samples (2 mL per sample) is taken at the following time-points:
- the steady state PK can be collected on Day 1 to Day 4 Week 5 following multiple dosing on a 4 th 5 days on/ 2 days off dosing schedule): predose, 2, 4, 6, 8, 24, 48, and 72 hr post dose.
- Sample is collected at predose on Week 1 Day 1 and at predose on Week 4 Day 1 (or Week 5 Day 1 , if applicable)
- ECG evaluation predose (triplicate with 5-10 minutes apart), and within 1 hour after 2h and 6h postdose PK sampling);
- Non compartmental analysis is conducted on full PK profile of COMPOUND I. Summary statistics and mean (SD) plots is presented for COMPOUND I plasma concentration at each scheduled time point by hepatic group and dose for both single dose and steady state. Pharmacokinetic parameters such as Cmax, Tmax, AUClast, single-dose AUCinf, HL, Vz/F, CL/F is summarized by hepatic group and dose. Mild and moderate hepatic impairment groups is compared to the control group (normal hepatic function) for the PK parameters including Cmax, Tmax, AUClast, and single-dose AUCinf.
- a fixed effect ANOVA model is fit to the log- transformed dose-normalized primary PK parameters (Cmax, AUClast and single-dose AUCinf) from control, mild and moderate hepatic impairment groups, with hepatic function as the fixed effect if dose proportionality (DP) is a reasonable assumption.
- DP dose proportionality
- a point estimate and the corresponding 90% confidence interval for the mean difference between the control group and each hepatic impairment group is calculated. This is anti-logged to obtain the point estimate and 90% confidence interval for the ratio of the geometric means on the untransformed scale.
- the primary analysis is performed as described if there is further evidence for the DP assumption. Otherwise, other linear and/or non-linear model based analysis to assess the impact of hepatic function on COMPOUND I PK parameters may be employed as appropriate.
- the effect of baseline covariates such as age and weight is investigated, as necessary.
- PK data generated from this study contribute to the future meta-analysis for exploratory population PK of COMPOUND I in patients with normal or moderate
- Safety analysis consist of AE summaries (frequency tables) and listings, laboratory abnormalities summary (shift tables for baseline to worst post-baseline) and flagging of notable values in listings, and listing of other tests (e.g., electrocardiogram or vital signs).
- the Safety Set is used for safety analysis. DLTs is listed using the dose-determining set.
- Sample size for this study is primarily driven by feasiblity and simple dose finding procedure to identify the tolerated COMPOUND I dose in Treatment Groups 2 and 3 based on the dose levels assessed in this study. Approximately 18-48 patients are enrolled in study, with a minimum of 6 evaluable patients in Treatment Groups 1 , 2 and 3. The inter-subject coefficient of variation (CV%) for AUC was around 50% on the 500 mg/day on a 5 days on/2 days off dosing schedule.
- the precision or half-width of 90% confidence intervals (CI) for (impaired hepatic function)-(normal hepatic function) comparison on the log scale extends 0.494 from the observed difference in means. This calculation is based on a two sample t-test with a type I error rate of 10%. No adjustments were made for multiple comparisons.
- the above half width translates into the following 90% confidence intervals (CI) of pharmacokinetic parameter ratios assuming different observed ratios.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP12758976.0A EP2755655A1 (en) | 2011-09-15 | 2012-09-07 | Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients |
US14/342,612 US20140221389A1 (en) | 2011-09-15 | 2012-09-07 | Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients |
AU2012308993A AU2012308993A1 (en) | 2011-09-15 | 2012-09-07 | Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl]-1H-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients |
KR1020147006625A KR20140062485A (en) | 2011-09-15 | 2012-09-07 | Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients |
CA2848210A CA2848210A1 (en) | 2011-09-15 | 2012-09-07 | Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients |
RU2014114827/15A RU2014114827A (en) | 2011-09-15 | 2012-09-07 | APPLICATION OF 4-AMINO-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1h-benzimidazole-2-yl] -1h-quinolin-2-one for treating cancer in patients with moderate liver failure |
MX2014003182A MX2014003182A (en) | 2011-09-15 | 2012-09-07 | Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimid azol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients. |
IN2060DEN2014 IN2014DN02060A (en) | 2011-09-15 | 2012-09-07 | |
BR112014005653A BR112014005653A2 (en) | 2011-09-15 | 2012-09-07 | use of 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1h-benzimidazol-2-1l] 1h-quinolin-one to treat cancer in patients with moderate hepatic impairment |
JP2014530703A JP2014526506A (en) | 2011-09-15 | 2012-09-07 | 4-amino-5-fluoro-3- [6- (4-methylpiperazin-1-yl) -1H-benzimidazol-2-yl] -1H-quinolin-2-one in the treatment of cancer in patients with moderate liver injury use |
CN201280044613.4A CN103826634A (en) | 2011-09-15 | 2012-09-07 | Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161535142P | 2011-09-15 | 2011-09-15 | |
US61/535,142 | 2011-09-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2013039764A1 true WO2013039764A1 (en) | 2013-03-21 |
Family
ID=46846036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2012/054046 WO2013039764A1 (en) | 2011-09-15 | 2012-09-07 | Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients |
Country Status (12)
Country | Link |
---|---|
US (1) | US20140221389A1 (en) |
EP (1) | EP2755655A1 (en) |
JP (1) | JP2014526506A (en) |
KR (1) | KR20140062485A (en) |
CN (1) | CN103826634A (en) |
AU (1) | AU2012308993A1 (en) |
BR (1) | BR112014005653A2 (en) |
CA (1) | CA2848210A1 (en) |
IN (1) | IN2014DN02060A (en) |
MX (1) | MX2014003182A (en) |
RU (1) | RU2014114827A (en) |
WO (1) | WO2013039764A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3093014A1 (en) * | 2015-05-13 | 2016-11-16 | Aventis Pharma S.A. | Cabazitaxel and its use for treating cancer |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6605617B2 (en) | 2000-09-11 | 2003-08-12 | Chiron Corporation | Quinolinone derivatives |
WO2004043389A2 (en) * | 2002-11-13 | 2004-05-27 | Chiron Corporation | Methods of treating cancer and related methods |
WO2004105763A2 (en) * | 2003-05-27 | 2004-12-09 | Haegerkvist Robert Per | Use of tyrosine kinase inhibitor to treat diabetes |
WO2006127926A2 (en) | 2005-05-23 | 2006-11-30 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
US7470709B2 (en) | 2002-08-23 | 2008-12-30 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
WO2009115562A2 (en) | 2008-03-19 | 2009-09-24 | Novartis Ag | Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100377709C (en) * | 2002-11-13 | 2008-04-02 | 希龙公司 | Methods of treating cancer and related methods |
AU2010321533A1 (en) * | 2009-11-23 | 2012-05-31 | Cerulean Pharma Inc. | Cyclodextrin-based polymers for therapeutic delivery |
-
2012
- 2012-09-07 MX MX2014003182A patent/MX2014003182A/en not_active Application Discontinuation
- 2012-09-07 EP EP12758976.0A patent/EP2755655A1/en not_active Withdrawn
- 2012-09-07 CN CN201280044613.4A patent/CN103826634A/en active Pending
- 2012-09-07 US US14/342,612 patent/US20140221389A1/en not_active Abandoned
- 2012-09-07 RU RU2014114827/15A patent/RU2014114827A/en not_active Application Discontinuation
- 2012-09-07 AU AU2012308993A patent/AU2012308993A1/en not_active Abandoned
- 2012-09-07 JP JP2014530703A patent/JP2014526506A/en active Pending
- 2012-09-07 IN IN2060DEN2014 patent/IN2014DN02060A/en unknown
- 2012-09-07 KR KR1020147006625A patent/KR20140062485A/en not_active Application Discontinuation
- 2012-09-07 WO PCT/US2012/054046 patent/WO2013039764A1/en active Application Filing
- 2012-09-07 BR BR112014005653A patent/BR112014005653A2/en not_active IP Right Cessation
- 2012-09-07 CA CA2848210A patent/CA2848210A1/en not_active Abandoned
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6605617B2 (en) | 2000-09-11 | 2003-08-12 | Chiron Corporation | Quinolinone derivatives |
US6774237B2 (en) | 2000-09-11 | 2004-08-10 | Chiron Corporation | Quinolinone derivatives |
US7335774B2 (en) | 2000-09-11 | 2008-02-26 | Novartis Vaccines And Diagnostics, Inc. | Quinolinone derivatives |
US7470709B2 (en) | 2002-08-23 | 2008-12-30 | Novartis Vaccines And Diagnostics, Inc. | Benzimidazole quinolinones and uses thereof |
WO2004043389A2 (en) * | 2002-11-13 | 2004-05-27 | Chiron Corporation | Methods of treating cancer and related methods |
WO2004105763A2 (en) * | 2003-05-27 | 2004-12-09 | Haegerkvist Robert Per | Use of tyrosine kinase inhibitor to treat diabetes |
WO2006127926A2 (en) | 2005-05-23 | 2006-11-30 | Novartis Ag | Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts |
WO2009115562A2 (en) | 2008-03-19 | 2009-09-24 | Novartis Ag | Crystalline forms and two solvated forms of 4-amino-5-fluoro-3-[5-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]quinolin-2(1h)-one lactic acid salts |
Non-Patent Citations (9)
Title |
---|
ANDRE F ET AL: "Study CTKI258A2202: A multicenter, open-label phase II trial of dovitinib (TKI258) in FGFR1-amplified and nonamplified HER2-negative metastatic breast cancer", vol. 28, no. 15 ,supplement, 1 June 2010 (2010-06-01), pages TPS122, XP002678913, ISSN: 0732-183X, Retrieved from the Internet <URL:http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/TPS122?sid=2866ba95-653f-45d5-9863-86d9027a4a7d> [retrieved on 20121116] * |
D. SARKER ET AL: "A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors", CLINICAL CANCER RESEARCH, vol. 14, no. 7, 1 April 2008 (2008-04-01), pages 2075 - 2081, XP055044441, ISSN: 1078-0432, DOI: 10.1158/1078-0432.CCR-07-1466 * |
E. ANGEVIN ET AL.: "A phase I/II study of dovitinib (TKI258), a FGFR and VEGFR inhibitor, in patients (pts) with advanced or metastatic renal cell cancer: Phase I results.", June 2010 (2010-06-01), XP002687361, Retrieved from the Internet <URL:http://meeting.ascopubs.org/cgi/content/abstract/28/15_suppl/3057> [retrieved on 20121116] * |
E. ANGEVIN ET AL.: "A phase II study of dovitinib (TKI258), an FGFR- and VEGFR-inhibitor, in patients with advanced or metastatic renal cell cancer (mRCC).", June 2011 (2011-06-01), XP002687360, Retrieved from the Internet <URL:http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/4551> [retrieved on 20121116] * |
E. ANGEVIN ET AL.: "TKI258 (dovitinib lactate) in metastatic renal cell carcinoma (mRCC) patients refractory to approved targeted therapies: A phase I/II dose finding and biomarker study", June 2009 (2009-06-01), XP002687362, Retrieved from the Internet <URL:http://meeting.ascopubs.org/cgi/content/abstract/27/15S/3563> [retrieved on 20121116] * |
F. ANDRE ET AL: "A multicenter, open-label phase II trial of dovitinib, an FGFR1 inhibitor, in FGFR1 amplified and non-amplified metastatic breast cancer.", June 2011 (2011-06-01), XP002687363, Retrieved from the Internet <URL:http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/508> [retrieved on 20121116] * |
J. T. LETTIERI, A. L. MAZZU, L. HUANG AND C. D. LATHIA: "Effect of hepatic impairment on sorafenib pharmacokinetics: Results of a multicenter, open-label, single-dose, phase I trial.", June 2011 (2011-06-01), XP002687365, Retrieved from the Internet <URL:http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/2580?sid=7c292375-8afa-4cf6-ba9b-ad39c1d15ac0> [retrieved on 20121116] * |
M. B. LODISH ET AL: "Endocrine side effects of broad-acting kinase inhibitors", ENDOCRINE RELATED CANCER, vol. 17, no. 3, 5 July 2010 (2010-07-05), pages R233 - R244, XP055044437, ISSN: 1351-0088, DOI: 10.1677/ERC-10-0082 * |
W. M. D. TAI ET AL: "A phase I study of dovitinib in combination with capecitabine and oxaliplatin in upfront treatment of advanced colorectal and gastric cancer with a dose expansion cohort in advanced gastric cancer.", June 2011 (2011-06-01), XP002687364, Retrieved from the Internet <URL:http://meeting.ascopubs.org/cgi/content/abstract/29/15_suppl/TPS174> [retrieved on 20121116] * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
Also Published As
Publication number | Publication date |
---|---|
US20140221389A1 (en) | 2014-08-07 |
AU2012308993A1 (en) | 2014-03-27 |
EP2755655A1 (en) | 2014-07-23 |
MX2014003182A (en) | 2014-09-22 |
BR112014005653A2 (en) | 2017-03-28 |
KR20140062485A (en) | 2014-05-23 |
IN2014DN02060A (en) | 2015-05-15 |
JP2014526506A (en) | 2014-10-06 |
CN103826634A (en) | 2014-05-28 |
CA2848210A1 (en) | 2013-03-21 |
RU2014114827A (en) | 2015-10-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11419870B2 (en) | Intermittent dosing of MDM2 inhibitor | |
WO2017201156A1 (en) | Method of treating kras wild-type metastatic colorectal cell carcinoma using cabozantinib plus panitumumab | |
EA034512B1 (en) | Treatment of cancer with tor kinase inhibitors | |
TW201517918A (en) | Sensitizer for cancer radiotherapy | |
JP7278405B2 (en) | Use of kiauranib in the treatment of small cell lung cancer | |
WO2013039764A1 (en) | Use of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one in the treatment of cancer in moderate hepatic impaired patients | |
KR20210126654A (en) | cancer treatment | |
US20230102483A1 (en) | [6r]-mthf in 5-fu based chemotherapy of left-sided colorectal cancer | |
US20210379095A1 (en) | Methods and Combination Therapy to Treat Biliary Tract Cancer | |
KR20220124739A (en) | Combination Therapy for the Treatment of Cancer | |
CN114641293A (en) | Application of FGFR inhibitor | |
KR20150003786A (en) | Methods for treating cancer using pi3k inhibitor and mek inhibitor | |
US20230097085A1 (en) | [6r]-mthf in 5-fu based chemotherapy of right-sided colorectal cancer | |
US20230233695A1 (en) | Mithramycin a nanoparticles for cancer treatment | |
RU2793543C2 (en) | Methods and combined therapeutic product for the treatment of bile ducts cancer | |
US11382892B2 (en) | Method for administration | |
TW202416986A (en) | Methods of treating disorders with ulk inhibitors | |
WO2024046405A1 (en) | Use of egfr kinase inhibitor | |
US20060106026A1 (en) | 4-(4-methylpiperazin-1-ylmethyl)-n-[4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl]-benzamide for treating anaplastic thyroid cancer | |
CN114617969A (en) | Application of lenvatinib and Aurora-A kinase inhibitor in preparation of drugs for inhibiting cancers | |
Li | Molecular imaging for characterization of lymphoma biology and monitoring response to cancer drug therapy | |
WO2011066545A1 (en) | Treatment of human osteosarcoma |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12758976 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 14342612 Country of ref document: US |
|
REEP | Request for entry into the european phase |
Ref document number: 2012758976 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012758976 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2848210 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 20147006625 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014530703 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2014/003182 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2012308993 Country of ref document: AU Date of ref document: 20120907 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2014114827 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014005653 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112014005653 Country of ref document: BR Kind code of ref document: A2 Effective date: 20140312 |